These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 1265555

  • 21. [Treatment with monocomponent semi-lente insulin in diabetes of difficult compensation].
    Barbero L, Gamba S, Zanno C, Regis G, Bruni B.
    Minerva Med; 1978 Apr 30; 69(21):1437-42. PubMed ID: 683547
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Transfer from purified porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents. A two-year follow-up.
    Dorchy H, Duchateau J, Bosson D, D'Hooge D.
    Diabete Metab; 1989 Apr 30; 15(3):107-10. PubMed ID: 2668052
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [The place of "monocomponent" insulins in diabetes mellitus therapy].
    Teuscher A.
    Schweiz Med Wochenschr; 1975 Apr 19; 105(16):485-94. PubMed ID: 1215860
    [Abstract] [Full Text] [Related]

  • 28. The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies.
    Anderson OO.
    Acta Endocrinol (Copenh); 1975 Apr 19; 78(4):723-35. PubMed ID: 1173962
    [Abstract] [Full Text] [Related]

  • 29. [Effect of monocomponent insulin serum anti-insulin antibody levels (author's transl)].
    García de los Ríos M, Mella I, Durruty P, Ruiz F, López G, Tapia JC, González G.
    Rev Med Chil; 1981 Jun 19; 109(6):509-15. PubMed ID: 7036310
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Monocomponent insulin in maturity onset diabetes mellitus.
    Viswanathan M, Ramachandran A, Snehalatha C, Viswanathan M.
    J Indian Med Assoc; 1981 Mar 01; 76(5):73-5. PubMed ID: 7021694
    [No Abstract] [Full Text] [Related]

  • 32. [The study of insulin antibodies in different forms of diabetes mellitus].
    Mincu I, Ionescu-Tirgovişte C, Cheţa D, Simionescu L, Mirodon Z, Vasilescu V, Bruckner I.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979 Mar 01; 31(5):421-8. PubMed ID: 44565
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Monocomponent insulin: general considerations].
    Rodriguez-Miñon JL, Rios MS.
    Journ Annu Diabetol Hotel Dieu; 1978 Mar 01; ():109-22. PubMed ID: 651088
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Insulin antibody formation during long-term treatment with monocomponent and monospecies insulin.
    Piers DA, Sluiter WJ, Reitsma WD, Doorenbos H.
    Neth J Med; 1974 Mar 01; 17(4-5):234-8. PubMed ID: 4465730
    [No Abstract] [Full Text] [Related]

  • 39. [Use of high-purity insulins in the treatment of patients with diabetes mellitus].
    Spesivtseva VG, Pokryshkin VI, Belokrinitskiĭ, Koroleva TV, Mamaeva GG.
    Ter Arkh; 1987 Mar 01; 59(11):22-6. PubMed ID: 3327181
    [Abstract] [Full Text] [Related]

  • 40. [Proceedings: 2 years of experiences with monocomponent insulin in diabetic patients].
    Fankhauser S, Michl J, Morell B.
    Helv Med Acta; 1974 May 01; 37(5-6):365-6. PubMed ID: 4605883
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.